<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36111770</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-6190</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>5</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Current neuropharmacology</Title><ISOAbbreviation>Curr Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Boosting Mitochondrial Potential: An Imperative Therapeutic Intervention in Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>1117</StartPage><EndPage>1138</EndPage><MedlinePgn>1117-1138</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1570159X20666220915092703</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic Lateral Sclerosis (ALS) is a progressive and terminal neurodegenerative disorder. Mitochondrial dysfunction, imbalance of cellular bioenergetics, electron chain transportation and calcium homeostasis are deeply associated with the progression of this disease. Impaired mitochondrial functions are crucial in rapid neurodegeneration. The mitochondria of ALS patients are associated with deregulated Ca<sup>2+</sup> homeostasis and elevated levels of reactive oxygen species (ROS), leading to oxidative stress. Overload of mitochondrial calcium and ROS production leads to glutamatereceptor mediated neurotoxicity. This implies mitochondria are an attractive therapeutic target.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this review is to brief the latest developments in the understanding of mitochondrial pathogenesis in ALS and emphasize the restorative capacity of therapeutic candidates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In ALS, mitochondrial dysfunction is a well-known phenomenon. Various therapies targeted towards mitochondrial dysfunction aim at decreasing ROS generation, increasing mitochondrial biogenesis, and inhibiting apoptotic pathways. Some of the therapies briefed in this review may be categorized as synthetic, natural compounds, genetic materials, and cellular therapies.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The overarching goals of mitochondrial therapies in ALS are to benefit ALS patients by slowing down the disease progression and prolonging overall survival. Despite various therapeutic approaches, there are many hurdles in the development of a successful therapy due to the multifaceted nature of mitochondrial dysfunction and ALS progression. Intensive research is required to precisely elucidate the molecular pathways involved in the progression of mitochondrial dysfunctions that ultimately lead to ALS. Because of the multifactorial nature of ALS, a combination therapy approach may hold the key to cure and treat ALS in the future.</AbstractText><CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dhasmana</LastName><ForeName>Swati</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Immunology &amp; Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhasmana</LastName><ForeName>Anupam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology &amp; Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Himalayan School of Biosciences, Swami Rama Himalayan University, Dehradun, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotnala</LastName><ForeName>Sudhir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Immunology &amp; Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangtani</LastName><ForeName>Varsha</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Immunology &amp; Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narula</LastName><ForeName>Acharan S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Narula Research LLC, 107 Boulder Bluff, Chapel Hill, North Carolina, NC 27516, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haque</LastName><ForeName>Shafiul</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, 45142, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaggi</LastName><ForeName>Meena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology &amp; Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yallapu</LastName><ForeName>Murali M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Immunology &amp; Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chauhan</LastName><ForeName>Subhash C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Immunology &amp; Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Neuropharmacol</MedlineTA><NlmUniqueID>101157239</NlmUniqueID><ISSNLinking>1570-159X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">ROS in ALS</Keyword><Keyword MajorTopicYN="N">excitotoxicity</Keyword><Keyword MajorTopicYN="N">mitochondrial biogenesis</Keyword><Keyword MajorTopicYN="N">mitochondrial dysfunction</Keyword><Keyword MajorTopicYN="N">mitochondrial reactivation</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest, financial or otherwise.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>16</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36111770</ArticleId><ArticleId IdType="pmc">PMC10286590</ArticleId><ArticleId IdType="doi">10.2174/1570159X20666220915092703</ArticleId><ArticleId IdType="pii">CN-EPUB-126324</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goutman S.A. Diagnosis and clinical management of amyotrophic lateral sclerosis and other motor neuron disorders. Continuum (Minneap. Minn.) 2017;23(5):1332&#x2013;1359. doi: 10.1212/CON.0000000000000535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CON.0000000000000535</ArticleId><ArticleId IdType="pubmed">28968365</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27(10):1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Chi&#xf2; A., Traynor B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17(1):17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K. Familial amyotrophic lateral sclerosis. Neurol. Clin. 2015;33(4):807&#x2013;830. doi: 10.1016/j.ncl.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.001</ArticleId><ArticleId IdType="pmc">PMC4670044</ArticleId><ArticleId IdType="pubmed">26515623</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards D., Morren J.A., Pioro E.P. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J. Neurol. Sci. 2020:417117054. doi: 10.1016/j.jns.2020.117054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117054</ArticleId><ArticleId IdType="pubmed">32763509</ArticleId></ArticleIdList></Reference><Reference><Citation>Maskovic J., Ilic A., Zugic V., Stevic Z., Stjepanovic M.I. What is the right moment for noninvasive ventilation in amyotrophic lateral sclerosis? AMS. 2019 doi: 10.5114/aoms.2019.90465.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms.2019.90465</ArticleId><ArticleId IdType="pmc">PMC10074320</ArticleId><ArticleId IdType="pubmed">37034525</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J., Pender N.P., Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6(11):994&#x2013;1003. doi: 10.1016/S1474-4422(07)70265-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70265-X</ArticleId><ArticleId IdType="pubmed">17945153</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B., Boum&#xe9;diene F., Logroscino G., Couratier P., Babron M.C., Leutenegger A.L., Copetti M., Preux P.M., Beghi E. Variation in worldwide incidence of amyotrophic lateral sclerosis: A meta-analysis. Int. J. Epidemiol. 2017;46(1):57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M.Y. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2017;377(2):162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H., Jr, Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539(7628):197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Sever B., Ciftci H., DeMirci H., Sever H., Ocak F., Yulug B., Tateishi H., Tateishi T., Otsuka M., Fujita M., Ba&#x15f;ak A.N. Comprehensive research on past and future therapeutic strategies devoted to treatment of amyotrophic lateral sclerosis. Int. J. Mol. Sci. 2022;23(5):2400. doi: 10.3390/ijms23052400.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23052400</ArticleId><ArticleId IdType="pmc">PMC8910198</ArticleId><ArticleId IdType="pubmed">35269543</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat P.F., Kabashi E., Desnuelle C. Deciphering spreading mechanisms in amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2015;28(5):455&#x2013;461. doi: 10.1097/WCO.0000000000000239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000239</ArticleId><ArticleId IdType="pubmed">26356410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Kim H.J. Prion-like mechanism in amyotrophic lateral sclerosis: Are protein aggregates the key? Exp. Neurobiol. 2015;24(1):1&#x2013;7. doi: 10.5607/en.2015.24.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2015.24.1.1</ArticleId><ArticleId IdType="pmc">PMC4363329</ArticleId><ArticleId IdType="pubmed">25792864</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S., McLean J., Robertson J. Neuronal intermediate filaments and ALS: A new look at an old question. Biochim. Biophys. Acta Mol. Basis Dis. 2006;1762(11-12):1001&#x2013;1012. doi: 10.1016/j.bbadis.2006.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.09.003</ArticleId><ArticleId IdType="pubmed">17045786</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrador E., Salvador-Palmer R., L&#xf3;pez-Blanch R., Jihad-Jebbar A., Vall&#xe9;s S.L., Estrela J.M. The link between oxidative stress, redox status, bioenergetics and mitochondria in the pathophysiology of ALS. Int. J. Mol. Sci. 2021;22(12):6352. doi: 10.3390/ijms22126352.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22126352</ArticleId><ArticleId IdType="pmc">PMC8231819</ArticleId><ArticleId IdType="pubmed">34198557</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckman J.S., Est&#xe9;vez A.G., Crow J.P., Barbeito L. Superoxide dismutase and the death of motoneurons in ALS. Trends Neurosci. 2001;24(11) Suppl.:S15&#x2013;S20. doi: 10.1016/S0166-2236(00)01981-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(00)01981-0</ArticleId><ArticleId IdType="pubmed">11881740</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel S.H., Zhao W., Beers D.R., Henkel J.S. The microglial-motoneuron dialogue in ALS. Acta Myol. 2011;30(1):4&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185827</ArticleId><ArticleId IdType="pubmed">21842586</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Beers D.R., Appel S.H. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. Neuroimmune Pharmacol. 2013;8(4):888&#x2013;899. doi: 10.1007/s11481-013-9489-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P., Eggett C.J. Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis. J. Neurol. 2000;247(S1) Suppl. 1:I17&#x2013;I27. doi: 10.1007/BF03161151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03161151</ArticleId><ArticleId IdType="pubmed">10795883</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki S., Sobue G. Importance of functional loss of FUS in FTLD/ALS. Front. Mol. Biosci. 2018;5:44. doi: 10.3389/fmolb.2018.00044.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2018.00044</ArticleId><ArticleId IdType="pmc">PMC5943504</ArticleId><ArticleId IdType="pubmed">29774215</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A., Bharathi V., Sivalingam V., Girdhar A., Patel B.K. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2019;12:25. doi: 10.3389/fnmol.2019.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R., Barbagallo P., Talbot K. The role of mitochondrial dysfunction and ER stress in TDP-43 and C9orf72 ALS. Front. Cell. Neurosci. 2021;15:653688. doi: 10.3389/fncel.2021.653688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.653688</ArticleId><ArticleId IdType="pmc">PMC8047135</ArticleId><ArticleId IdType="pubmed">33867942</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhasmana S., Dhasmana A., Narula A.S., Jaggi M., Yallapu M.M., Chauhan S.C. The panoramic view of amyotrophic lateral sclerosis: A fatal intricate neurological disorder. Life Sci. 2022:288120156. doi: 10.1016/j.lfs.2021.120156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2021.120156</ArticleId><ArticleId IdType="pubmed">34801512</ArticleId></ArticleIdList></Reference><Reference><Citation>Salemi M., Cosentino F., Lanza G., Cantone M., Salluzzo M.G., Giurato G. mRNA expression profiling of mitochondrial subunits in subjects with Parkinson&#x2019;s disease. AMS. 2023;19(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10259399</ArticleId><ArticleId IdType="pubmed">37313207</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins C.M.J., Jung C., Xu Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci. 2003;4(1):16. doi: 10.1186/1471-2202-4-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-4-16</ArticleId><ArticleId IdType="pmc">PMC169170</ArticleId><ArticleId IdType="pubmed">12864925</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali&#xf3; M.L., Henriques E., Siena A., Bertoncini C.R.A., Gil-Mohapel J., Rosenstock T.R. Mitochondrial dysfunction, neurogenesis, and epigenetics: Putative implications for amyotrophic lateral sclerosis neurodegeneration and treatment. Front. Neurosci. 2020;14:679. doi: 10.3389/fnins.2020.00679.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00679</ArticleId><ArticleId IdType="pmc">PMC7373761</ArticleId><ArticleId IdType="pubmed">32760239</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrador E., Salvador R., L&#xf3;pez-Blanch R., Jihad-Jebbar A., Vall&#xe9;s S.L., Estrela J.M. Oxidative stress, neuroinflammation and mitochondria in the pathophysiology of amyotrophic lateral sclerosis. Antioxidants. 2020;9(9):901. doi: 10.3390/antiox9090901.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9090901</ArticleId><ArticleId IdType="pmc">PMC7555310</ArticleId><ArticleId IdType="pubmed">32971909</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeineddine R., Farrawell N.E., Lambert-Smith I.A., Yerbury J.J. Addition of exogenous SOD1 aggregates causes TDP-43 mislocalisation and aggregation. Cell Stress Chaperones. 2017;22(6):893&#x2013;902. doi: 10.1007/s12192-017-0804-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-017-0804-y</ArticleId><ArticleId IdType="pmc">PMC5655364</ArticleId><ArticleId IdType="pubmed">28560609</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortob&#xe1;gyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., Ganesalingam J., Williams K.L., Tripathi V., Al-Saraj S., Al-Chalabi A., Leigh P.N., Blair I.P., Nicholson G., de Belleroche J., Gallo J.M., Miller C.C., Shaw C.E. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Guo L., Li M., Wei C., Li S., Xu R. The pathogenesis of amyotrophic lateral sclerosis: Mitochondrial dysfunction, protein misfolding and epigenetics. Brain Res. 2022:1786147904. doi: 10.1016/j.brainres.2022.147904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2022.147904</ArticleId><ArticleId IdType="pubmed">35390335</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T.J., Jr, Bosco D.A., LeClerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., Valdmanis P., Rouleau G.A., Hosler B.A., Cortelli P., de Jong P.J., Yoshinaga Y., Haines J.L., Pericak-Vance M.A., Yan J., Ticozzi N., Siddique T., McKenna-Yasek D., Sapp P.C., Horvitz H.R., Landers J.E., Brown R.H., Jr Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Kausar S., Wang F., Cui H. The role of mitochondria in reactive oxygen species generation and its implications for neurodegenerative diseases. Cells. 2018;7(12):274. doi: 10.3390/cells7120274.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells7120274</ArticleId><ArticleId IdType="pmc">PMC6316843</ArticleId><ArticleId IdType="pubmed">30563029</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P., Belford M.E., Lennon N., Bacskai B.J., Hyman B.T., Trotti D., Brown R.H., Jr Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron. 2004;43(1):19&#x2013;30. doi: 10.1016/j.neuron.2004.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.06.021</ArticleId><ArticleId IdType="pubmed">15233914</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J., Wang P., Chen X., Cheng H., Liu J., Fushimi K., Zhu L., Wu J.Y. FUS interacts with ATP synthase beta subunit and induces mitochondrial unfolded protein response in cellular and animal models. Proc. Natl. Acad. Sci. USA. 2018;115(41):E9678&#x2013;E9686. doi: 10.1073/pnas.1806655115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1806655115</ArticleId><ArticleId IdType="pmc">PMC6187197</ArticleId><ArticleId IdType="pubmed">30249657</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodavati M., Wang H., Hegde M.L. Altered mitochondrial dynamics in motor neuron disease: An emerging perspective. Cells. 2020;9(4):1065. doi: 10.3390/cells9041065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9041065</ArticleId><ArticleId IdType="pmc">PMC7226538</ArticleId><ArticleId IdType="pubmed">32344665</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R., Lu Y., Gendron T.F., Karydas A., Tran H., Yang D., Petrucelli L., Miller B.L., Almeida S., Gao F.B. Poly(GR) in C9orf72-related ALS/FTD compromises mitochondrial function and increases oxidative stress and DNA damage in iPSC-derived motor neurons. Neuron. 2016;92(2):383&#x2013;391. doi: 10.1016/j.neuron.2016.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.015</ArticleId><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.Y., Lopez-Gonzalez R., Krishnan G., Phillips H.L., Li A.N., Seeley W.W., Yao W.D., Almeida S., Gao F.B. C9orf72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo. Nat. Neurosci. 2019;22(6):851&#x2013;862. doi: 10.1038/s41593-019-0397-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0397-0</ArticleId><ArticleId IdType="pmc">PMC6800116</ArticleId><ArticleId IdType="pubmed">31086314</ArticleId></ArticleIdList></Reference><Reference><Citation>Onesto E., Colombrita C., Gumina V., Borghi M.O., Dusi S., Doretti A., Fagiolari G., Invernizzi F., Moggio M., Tiranti V., Silani V., Ratti A. Gene-specific mitochondria dysfunctions in human TARDBP and C9orf72 fibroblasts. Acta Neuropathol. Commun. 2016;4(1):47. doi: 10.1186/s40478-016-0316-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0316-5</ArticleId><ArticleId IdType="pmc">PMC4858818</ArticleId><ArticleId IdType="pubmed">27151080</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannwarth S., Ait-El-Mkadem S., Chaussenot A., Genin E.C., Lacas-Gervais S., Fragaki K., Berg-Alonso L., Kageyama Y., Serre V., Moore D.G., Verschueren A., Rouzier C., Le Ber I., Aug&#xe9; G., Cochaud C., Lespinasse F., N&#x2019;Guyen K., de Septenville A., Brice A., Yu-Wai-Man P., Sesaki H., Pouget J., Paquis-Flucklinger V. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain. 2014;137(8):2329&#x2013;2345. doi: 10.1093/brain/awu138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu138</ArticleId><ArticleId IdType="pmc">PMC4107737</ArticleId><ArticleId IdType="pubmed">24934289</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J., Yang M., Chen Y., Chen X., Liu J., Sun S., Cheng H., Li Y., Bigio E.H., Mesulam M., Xu Q., Du S., Fushimi K., Zhu L., Wu J.Y. FUS Interacts with HSP60 to Promote Mitochondrial Damage. PLoS Genet. 2015;11(9):e1005357. doi: 10.1371/journal.pgen.1005357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1005357</ArticleId><ArticleId IdType="pmc">PMC4559378</ArticleId><ArticleId IdType="pubmed">26335776</ArticleId></ArticleIdList></Reference><Reference><Citation>Fivenson E.M., Lautrup S., Sun N., Scheibye-Knudsen M., Stevnsner T., Nilsen H., Bohr V.A., Fang E.F. Mitophagy in neurodegeneration and aging. Neurochem. Int. 2017;109:202&#x2013;209. doi: 10.1016/j.neuint.2017.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2017.02.007</ArticleId><ArticleId IdType="pmc">PMC5565781</ArticleId><ArticleId IdType="pubmed">28235551</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E.F., Shaw P.J., De Vos K.J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 2019:710132933. doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldovan M., Rosberg M.R., Alvarez S., Klein D., Martini R., Krarup C. Aging-associated changes in motor axon voltage-gated Na+ channel function in mice. Neurobiol. Aging. 2016;39:128&#x2013;139. doi: 10.1016/j.neurobiolaging.2015.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.12.005</ArticleId><ArticleId IdType="pubmed">26923409</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentine J.M., Li M.E., Shoelson S.E., Zhang N., Reddick R.L., Musi N. NF&#x3ba;B regulates muscle development and mitochondrial function. J. Gerontol. A Biol. Sci. Med. Sci. 2020;75(4):647&#x2013;653. doi: 10.1093/gerona/gly262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/gly262</ArticleId><ArticleId IdType="pmc">PMC7328192</ArticleId><ArticleId IdType="pubmed">30423026</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G.H., Kim J.E., Rhie S.J., Yoon S. The role of oxidative stress in neurodegenerative diseases. Exp. Neurobiol. 2015;24(4):325&#x2013;340. doi: 10.5607/en.2015.24.4.325.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2015.24.4.325</ArticleId><ArticleId IdType="pmc">PMC4688332</ArticleId><ArticleId IdType="pubmed">26713080</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpern M., Brennand K.J., Gregory J. Examining the relationship between astrocyte dysfunction and neurodegeneration in ALS using hiPSCs. Neurobiol. Dis. 2019:132104562. doi: 10.1016/j.nbd.2019.104562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104562</ArticleId><ArticleId IdType="pmc">PMC6834907</ArticleId><ArticleId IdType="pubmed">31381978</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler J.P., Picchiarelli G., Dupuis L., Gonzalez De Aguilar J.L. The role of skeletal muscle in amyotrophic lateral sclerosis. Brain Pathol. 2016;26(2):227&#x2013;236. doi: 10.1111/bpa.12350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12350</ArticleId><ArticleId IdType="pmc">PMC8029271</ArticleId><ArticleId IdType="pubmed">26780251</ArticleId></ArticleIdList></Reference><Reference><Citation>Avci D., Lemberg M.K. Clipping or extracting: Two ways to membrane protein degradation. Trends Cell Biol. 2015;25(10):611&#x2013;622. doi: 10.1016/j.tcb.2015.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2015.07.003</ArticleId><ArticleId IdType="pubmed">26410407</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster C.P., Smith E.F., Shaw P.J., De Vos K.J. Protein homeostasis in amyotrophic lateral sclerosis: Therapeutic opportunities? Front. Mol. Neurosci. 2017;10:123. doi: 10.3389/fnmol.2017.00123.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00123</ArticleId><ArticleId IdType="pmc">PMC5411428</ArticleId><ArticleId IdType="pubmed">28512398</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica R., Paillusson S., Gomez-Suaga P., Mitchell J.C., Lau D.H.W., Gray E.H., Sancho R.M., Vizcay-Barrena G., De Vos K.J., Shaw C.E., Hanger D.P., Noble W., Miller C.C.J. ALS/FTD-associated FUS activates GSK-3&#x3b2; to disrupt the VAPB- PTPIP 51 interaction and ER-mitochondria associations. EMBO Rep. 2016;17(9):1326&#x2013;1342. doi: 10.15252/embr.201541726.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201541726</ArticleId><ArticleId IdType="pmc">PMC5007559</ArticleId><ArticleId IdType="pubmed">27418313</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica R., De Vos K.J., Paillusson S., Mueller S., Sancho R.M., Lau K.F., Vizcay-Barrena G., Lin W.L., Xu Y.F., Lewis J., Dickson D.W., Petrucelli L., Mitchell J.C., Shaw C.E., Miller C.C.J. ER&#x2013;mitochondria associations are regulated by the VAPB&#x2013;PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. Nat. Commun. 2014;5(1):3996. doi: 10.1038/ncomms4996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4996</ArticleId><ArticleId IdType="pmc">PMC4046113</ArticleId><ArticleId IdType="pubmed">24893131</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Saif A., Al-Mohanna F., Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann. Neurol. 2011;70(6):913&#x2013;919. doi: 10.1002/ana.22534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22534</ArticleId><ArticleId IdType="pubmed">21842496</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard-Marissal N., M&#xe9;dard J.J., Azzedine H., Chrast R. Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration. Brain. 2015;138(4):875&#x2013;890. doi: 10.1093/brain/awv008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv008</ArticleId><ArticleId IdType="pubmed">25678561</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollrath J.T., Sechi A., Dreser A., Katona I., Wiemuth D., Vervoorts J., Dohmen M., Chandrasekar A., Prause J., Brauers E., Jesse C.M., Weis J., Goswami A. Loss of function of the ALS protein SigR1 leads to ER pathology associated with defective autophagy and lipid raft disturbances. Cell Death Dis. 2014;5(6):e1290. doi: 10.1038/cddis.2014.243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.243</ArticleId><ArticleId IdType="pmc">PMC4611717</ArticleId><ArticleId IdType="pubmed">24922074</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamacher-Brady A., Brady N.R. Mitophagy programs: mechanisms and physiological implications of mitochondrial targeting by autophagy. Cell. Mol. Life Sci. 2016;73(4):775&#x2013;795. doi: 10.1007/s00018-015-2087-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-015-2087-8</ArticleId><ArticleId IdType="pmc">PMC4735260</ArticleId><ArticleId IdType="pubmed">26611876</ArticleId></ArticleIdList></Reference><Reference><Citation>Radke S., Chander H., Sch&#xe4;fer P., Meiss G., Kr&#xfc;ger R., Schulz J.B., Germain D. Mitochondrial protein quality control by the proteasome involves ubiquitination and the protease Omi. J. Biol. Chem. 2008;283(19):12681&#x2013;12685. doi: 10.1074/jbc.C800036200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C800036200</ArticleId><ArticleId IdType="pmc">PMC2442309</ArticleId><ArticleId IdType="pubmed">18362145</ArticleId></ArticleIdList></Reference><Reference><Citation>Majcher V, Goode A, James V, Layfield R. Autophagy receptor defects and ALS-FTLD. Mol Cell Neurosci. 2015;66(Pt A):43-52. doi: 10.1016/j.mcn.2015.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2015.01.002</ArticleId><ArticleId IdType="pubmed">25683489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikumar B., Sarkar S., Davies J.E., Futter M., Garcia-Arencibia M., Green-Thompson Z.W., Jimenez-Sanchez M., Korolchuk V.I., Lichtenberg M., Luo S., Massey D.C.O., Menzies F.M., Moreau K., Narayanan U., Renna M., Siddiqi F.H., Underwood B.R., Winslow A.R., Rubinsztein D.C. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol. Rev. 2010;90(4):1383&#x2013;1435. doi: 10.1152/physrev.00030.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00030.2009</ArticleId><ArticleId IdType="pubmed">20959619</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter B., Sliter D.A., Herhaus L., Stolz A., Wang C., Beli P., Zaffagnini G., Wild P., Martens S., Wagner S.A., Youle R.J., Dikic I. Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria. Proc. Natl. Acad. Sci. USA. 2016;113(15):4039&#x2013;4044. doi: 10.1073/pnas.1523926113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1523926113</ArticleId><ArticleId IdType="pmc">PMC4839414</ArticleId><ArticleId IdType="pubmed">27035970</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., M&#xfc;ller K., Marroquin N., Nordin F., H&#xfc;bers A., Weydt P., Pinto S., Press R., Millecamps S., Molko N., Bernard E., Desnuelle C., Soriani M.H., Dorst J., Graf E., Nordstr&#xf6;m U., Feiler M.S., Putz S., Boeckers T.M., Meyer T., Winkler A.S., Winkelman J., de Carvalho M., Thal D.R., Otto M., Br&#xe4;nnstr&#xf6;m T., Volk A.E., Kursula P., Danzer K.M., Lichtner P., Dikic I., Meitinger T., Ludolph A.C., Strom T.M., Andersen P.M., Weishaupt J.H. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18(5):631&#x2013;636. doi: 10.1038/nn.4000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., Ma C., Yi J., Wu S., Luo G., Xu X., Lin P.H., Sun J., Zhou J. Suppressed autophagy flux in skeletal muscle of an amyotrophic lateral sclerosis mouse model during disease progression. Physiol. Rep. 2015;3(1):e12271. doi: 10.14814/phy2.12271.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.12271</ArticleId><ArticleId IdType="pmc">PMC4387765</ArticleId><ArticleId IdType="pubmed">25602021</ArticleId></ArticleIdList></Reference><Reference><Citation>Goode A., Butler K., Long J., Cavey J., Scott D., Shaw B., Sollenberger J., Gell C., Johansen T., Oldham N.J., Searle M.S., Layfield R. Defective recognition of LC3B by mutant SQSTM1/p62 implicates impairment of autophagy as a pathogenic mechanism in ALS-FTLD. Autophagy. 2016;12(7):1094&#x2013;1104. doi: 10.1080/15548627.2016.1170257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2016.1170257</ArticleId><ArticleId IdType="pmc">PMC4990988</ArticleId><ArticleId IdType="pubmed">27158844</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Chen Y., Li X., Zhang W., Liu Z., Wu M., Pan Q., Liu H. Emerging role of transcription factor EB in mitochondrial quality control. Biomed. Pharmacother. 2020:128110272. doi: 10.1016/j.biopha.2020.110272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110272</ArticleId><ArticleId IdType="pubmed">32447212</ArticleId></ArticleIdList></Reference><Reference><Citation>Moya G.E., Rivera P.D., Dittenhafer-Reed K.E. Evidence for the role of mitochondrial DNA release in the inflammatory response in neurological disorders. Int. J. Mol. Sci. 2021;22(13):7030. doi: 10.3390/ijms22137030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22137030</ArticleId><ArticleId IdType="pmc">PMC8268735</ArticleId><ArticleId IdType="pubmed">34209978</ArticleId></ArticleIdList></Reference><Reference><Citation>Grazioli S., Pugin J. Mitochondrial damage-associated molecular patterns: From inflammatory signaling to human diseases. Front. Immunol. 2018;9:832. doi: 10.3389/fimmu.2018.00832.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00832</ArticleId><ArticleId IdType="pmc">PMC5946030</ArticleId><ArticleId IdType="pubmed">29780380</ArticleId></ArticleIdList></Reference><Reference><Citation>Itagaki K., Kaczmarek E., Lee Y.T., Tang I.T., Isal B., Adibnia Y., Sandler N., Grimm M.J., Segal B.H., Otterbein L.E., Hauser C.J. Mitochondrial DNA released by trauma induces neutrophil extracellular traps. PLoS One. 2015;10(3):e0120549. doi: 10.1371/journal.pone.0120549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0120549</ArticleId><ArticleId IdType="pmc">PMC4361684</ArticleId><ArticleId IdType="pubmed">25774524</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimada K., Crother T.R., Karlin J., Dagvadorj J., Chiba N., Chen S., Ramanujan V.K., Wolf A.J., Vergnes L., Ojcius D.M., Rentsendorj A., Vargas M., Guerrero C., Wang Y., Fitzgerald K.A., Underhill D.M., Town T., Arditi M. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36(3):401&#x2013;414. doi: 10.1016/j.immuni.2012.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.01.009</ArticleId><ArticleId IdType="pmc">PMC3312986</ArticleId><ArticleId IdType="pubmed">22342844</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchi L., Eigenbrod T., Mu&#xf1;oz-Planillo R., Nu&#xf1;ez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 2009;10(3):241&#x2013;247. doi: 10.1038/ni.1703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1703</ArticleId><ArticleId IdType="pmc">PMC2820724</ArticleId><ArticleId IdType="pubmed">19221555</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Veerdonk F.L., Netea M.G., Dinarello C.A., Joosten L.A.B. Inflammasome activation and IL-1&#x3b2; and IL-18 processing during infection. Trends Immunol. 2011;32(3):110&#x2013;116. doi: 10.1016/j.it.2011.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2011.01.003</ArticleId><ArticleId IdType="pubmed">21333600</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra S.R., Mahapatra K.K., Behera B.P., Patra S., Bhol C.S., Panigrahi D.P., Praharaj P.P., Singh A., Patil S., Dhiman R., Bhutia S.K. Mitochondrial dysfunction as a driver of NLRP3 inflammasome activation and its modulation through mitophagy for potential therapeutics. Int. J. Biochem. Cell Biol. 2021:136106013. doi: 10.1016/j.biocel.2021.106013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2021.106013</ArticleId><ArticleId IdType="pubmed">34022434</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E., King P.H., Si Y., Kwon Y., Varela V., Ibarburu S., Kovacs M., Moura I.C., Beckman J.S., Hermine O., Barbeito L. Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight. 2018;3(19):e123249. doi: 10.1172/jci.insight.123249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.123249</ArticleId><ArticleId IdType="pmc">PMC6237484</ArticleId><ArticleId IdType="pubmed">30282815</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi A.U., Minhas P.S., Liddelow S.A., Haileselassie B., Andreasson K.I., Dorn G.W., II, Mochly-Rosen D. Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration. Nat. Neurosci. 2019;22(10):1635&#x2013;1648. doi: 10.1038/s41593-019-0486-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0486-0</ArticleId><ArticleId IdType="pmc">PMC6764589</ArticleId><ArticleId IdType="pubmed">31551592</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A., Wu P.H., Hughes E.G., Fukaya M., Tischfield M.A., Langseth A.J., Wirtz D., Bergles D.E. Transient opening of the mitochondrial permeability transition pore induces microdomain calcium transients in astrocyte processes. Neuron. 2017;93(3):587&#x2013;605.e7. doi: 10.1016/j.neuron.2016.12.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.12.034</ArticleId><ArticleId IdType="pmc">PMC5308886</ArticleId><ArticleId IdType="pubmed">28132831</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M., Beeson G., Beeson C.C., Johnson J.A., Vargas M.R. Mitochondria-targeted catalase reverts the neurotoxicity of hSOD1G93A astrocytes without extending the survival of ALS-linked mutant hSOD1 mice. PLoS One. 2014;9(7):e103438. doi: 10.1371/journal.pone.0103438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0103438</ArticleId><ArticleId IdType="pmc">PMC4108402</ArticleId><ArticleId IdType="pubmed">25054289</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S.P., Hall B., Woof R., Francis L., Gatto N., Shaw A.C., Myszczynska M., Hemingway J., Coldicott I., Willcock A., Job L., Hughes R.M., Boschian C., Bayatti N., Heath P.R., Bandmann O., Mortiboys H., Ferraiuolo L., Shaw P.J. C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis. Brain. 2019;142(12):3771&#x2013;3790. doi: 10.1093/brain/awz302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz302</ArticleId><ArticleId IdType="pmc">PMC6906594</ArticleId><ArticleId IdType="pubmed">31647549</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011;11(11):723&#x2013;737. doi: 10.1038/nri3073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3073</ArticleId><ArticleId IdType="pmc">PMC3422549</ArticleId><ArticleId IdType="pubmed">21997792</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall D., Baloh R.H. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J. Clin. Invest. 2017;127(9):3250&#x2013;3258. doi: 10.1172/JCI90607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90607</ArticleId><ArticleId IdType="pmc">PMC5669558</ArticleId><ArticleId IdType="pubmed">28737506</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe5;nberg A., Skene N., Sanders F., Trusohamn M., Remnest&#xe5;l J., Szczepi&#x144;ska A., Aksoylu I.S., L&#xf6;nnerberg P., Ebarasi L., Wouters S., Lehmann M., Olofsson J., von Gohren Antequera I., Domaniku A., De Schaepdryver M., De Vocht J., Poesen K., Uhl&#xe9;n M., Anink J., Mijnsbergen C., Vergunst-Bosch H., H&#xfc;bers A., Kl&#xe4;ppe U., Rodriguez-Vieitez E., Gilthorpe J.D., Hedlund E., Harris R.A., Aronica E., Van Damme P., Ludolph A., Veldink J., Ingre C., Nilsson P., Lewandowski S.A. Altered perivascular fibroblast activity precedes ALS disease onset. Nat. Med. 2021;27(4):640&#x2013;646. doi: 10.1038/s41591-021-01295-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01295-9</ArticleId><ArticleId IdType="pmc">PMC7613336</ArticleId><ArticleId IdType="pubmed">33859435</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbaz Y., Schuldiner M. Staying in touch: the molecular era of organelle contact sites. Trends Biochem. Sci. 2011;36(11):616&#x2013;623. doi: 10.1016/j.tibs.2011.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2011.08.004</ArticleId><ArticleId IdType="pubmed">21958688</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S., Meng T., Huang H., Zhuang H., He Z., Yang H., Feng D. Molecular machineries and physiological relevance of ER-mediated membrane contacts. Theranostics. 2021;11(2):974&#x2013;995. doi: 10.7150/thno.51871.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.51871</ArticleId><ArticleId IdType="pmc">PMC7738843</ArticleId><ArticleId IdType="pubmed">33391516</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Yang J. Mitochondria-associated membranes: A hub for neurodegenerative diseases. Biomed. Pharmacother. 2022:149112890. doi: 10.1016/j.biopha.2022.112890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.112890</ArticleId><ArticleId IdType="pubmed">35367757</ArticleId></ArticleIdList></Reference><Reference><Citation>Maday S., Twelvetrees A.E., Moughamian A.J., Holzbaur E.L.F. Axonal transport: cargo-specific mechanisms of motility and regulation. Neuron. 2014;84(2):292&#x2013;309. doi: 10.1016/j.neuron.2014.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.10.019</ArticleId><ArticleId IdType="pmc">PMC4269290</ArticleId><ArticleId IdType="pubmed">25374356</ArticleId></ArticleIdList></Reference><Reference><Citation>Schon E.A., Area-Gomez E. Is Alzheimer&#x2019;s disease a disorder of mitochondria-associated membranes? J. Alzheimers Dis. 2010;20(s2) Suppl. 2:S281&#x2013;S292. doi: 10.3233/JAD-2010-100495.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-100495</ArticleId><ArticleId IdType="pubmed">20421691</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., Boillee S., Roberts E.A., Garcia M.L., McAlonis-Downes M., Mikse O.R., Cleveland D.W., Goldstein L.S.B. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc. Natl. Acad. Sci. USA. 2008;105(21):7594&#x2013;7599. doi: 10.1073/pnas.0802556105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0802556105</ArticleId><ArticleId IdType="pmc">PMC2396671</ArticleId><ArticleId IdType="pubmed">18492803</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddi A.R., Culotta V.C. SOD1 integrates signals from oxygen and glucose to repress respiration. Cell. 2013;152(1-2):224&#x2013;235. doi: 10.1016/j.cell.2012.11.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.11.046</ArticleId><ArticleId IdType="pmc">PMC3552299</ArticleId><ArticleId IdType="pubmed">23332757</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoshan-Barmatz V., Ben-Hail D. VDAC, a multi-functional mitochondrial protein as a pharmacological target. Mitochondrion. 2012;12(1):24&#x2013;34. doi: 10.1016/j.mito.2011.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2011.04.001</ArticleId><ArticleId IdType="pubmed">21530686</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosencrans W.M., Rajendran M., Bezrukov S.M., Rostovtseva T.K. VDAC regulation of mitochondrial calcium flux: From channel biophysics to disease. Cell Calcium. 2021:94102356. doi: 10.1016/j.ceca.2021.102356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2021.102356</ArticleId><ArticleId IdType="pmc">PMC7914209</ArticleId><ArticleId IdType="pubmed">33529977</ArticleId></ArticleIdList></Reference><Reference><Citation>Varughese J.T., Buchanan S.K., Pitt A.S. The role of voltage-dependent anion channel in mitochondrial dysfunction and human disease. Cells. 2021;10(7):1737. doi: 10.3390/cells10071737.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10071737</ArticleId><ArticleId IdType="pmc">PMC8305817</ArticleId><ArticleId IdType="pubmed">34359907</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S., Ilieva H., Tamada H., Nomura H., Komine O., Endo F., Jin S., Mancias P., Kiyama H., Yamanaka K. Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR1- and SOD1-linked ALS. EMBO Mol. Med. 2016;8(12):1421&#x2013;1437. doi: 10.15252/emmm.201606403.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606403</ArticleId><ArticleId IdType="pmc">PMC5167132</ArticleId><ArticleId IdType="pubmed">27821430</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Y., Hu J., Che Y., Liu Y., Luo Z., Cheng J., Han Q., He H., Zhou Q. CHCHD2 and CHCHD10 regulate mitochondrial dynamics and integrated stress response. Cell Death Dis. 2022;13(2):156. doi: 10.1038/s41419-022-04602-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-04602-5</ArticleId><ArticleId IdType="pmc">PMC8850591</ArticleId><ArticleId IdType="pubmed">35173147</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M., Gunay A., Chandel N.S., Ozdinler P.H. Mitochondrial dysregulation occurs early in ALS motor cortex with TDP-43 pathology and suggests maintaining NAD(+) balance as a therapeutic strategy. Sci Rep-Uk. 2022;12(1):4287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8917163</ArticleId><ArticleId IdType="pubmed">35277554</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M., Xie E.F., Kocak N., Ozdinler P.H. Mitoautophagy: A unique self-destructive path mitochondria of upper motor neurons with TDP-43 pathology take, very early in ALS. Front. Cell. Neurosci. 2019;13:489. doi: 10.3389/fncel.2019.00489.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00489</ArticleId><ArticleId IdType="pmc">PMC6854036</ArticleId><ArticleId IdType="pubmed">31787882</ArticleId></ArticleIdList></Reference><Reference><Citation>Cant&#xf3;-Santos J., Grau-Junyent J.M., Garrabou G. The impact of mitochondrial deficiencies in neuromuscular diseases. Antioxidants. 2020;9(10):964. doi: 10.3390/antiox9100964.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9100964</ArticleId><ArticleId IdType="pmc">PMC7600520</ArticleId><ArticleId IdType="pubmed">33050147</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Z., Wang W., Perry G., Zhu X., Wang X. Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis. Transl. Neurodegener. 2015;4(1):14. doi: 10.1186/s40035-015-0037-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-015-0037-x</ArticleId><ArticleId IdType="pmc">PMC4518588</ArticleId><ArticleId IdType="pubmed">26225210</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P.A., Henderson R.D. Effects of gender in amyotrophic lateral sclerosis. Gend. Med. 2010;7(6):557&#x2013;570. doi: 10.1016/j.genm.2010.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2010.11.010</ArticleId><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F., Siciliano M., Femiano C., Santangelo G., Lunetta C., Calvo A., Moglia C., Marinou K., Ticozzi N., Ferro C., Scial&#xf2; C., Sorar&#xf9; G., Conte A., Falzone Y.M., Tortelli R., Russo M., Sansone V.A., Chi&#xf2; A., Mora G., Silani V., Volanti P., Caponnetto C., Querin G., Sabatelli M., Riva N., Logroscino G., Messina S., Fasano A., Monsurr&#xf2; M.R., Tedeschi G., Mandrioli J. Comparative analysis of C9orf72 and sporadic disease in a large multicenter ALS population: The effect of male sex on survival of C9orf72 positive patients. Front. Neurosci. 2019;13:485. doi: 10.3389/fnins.2019.00485.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00485</ArticleId><ArticleId IdType="pmc">PMC6534038</ArticleId><ArticleId IdType="pubmed">31156370</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi C.I., Lee Y.D., Gwag B.J., Cho S.I., Kim S.S., Suh-Kim H. Effects of estrogen on lifespan and motor functions in female hSOD1 G93A transgenic mice. J. Neurol. Sci. 2008;268(1-2):40&#x2013;47. doi: 10.1016/j.jns.2007.10.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.10.024</ArticleId><ArticleId IdType="pubmed">18054961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Magran&#xe8; J., Starkov A.A., Manfredi G. The mitochondrial calcium regulator cyclophilin D is an essential component of oestrogen-mediated neuroprotection in amyotrophic lateral sclerosis. Brain. 2012;135(9):2865&#x2013;2874. doi: 10.1093/brain/aws208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws208</ArticleId><ArticleId IdType="pmc">PMC3437032</ArticleId><ArticleId IdType="pubmed">22961554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura-Clapier R., Moulin M., Piquereau J., Lemaire C., Mericskay M., Veksler V., Garnier A. Mitochondria: a central target for sex differences in pathologies. Clin. Sci. (Lond.) 2017;131(9):803&#x2013;822. doi: 10.1042/CS20160485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20160485</ArticleId><ArticleId IdType="pubmed">28424375</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacabelos D., Ram&#xed;rez-N&#xfa;&#xf1;ez O., Granado-Serrano A.B., Torres P., Ayala V., Moiseeva V., Povedano M., Ferrer I., Pamplona R., Portero-Otin M., Boada J. Early and gender-specific differences in spinal cord mitochondrial function and oxidative stress markers in a mouse model of ALS. Acta Neuropathol. Commun. 2016;4(1):3. doi: 10.1186/s40478-015-0271-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0271-6</ArticleId><ArticleId IdType="pmc">PMC4711180</ArticleId><ArticleId IdType="pubmed">26757991</ArticleId></ArticleIdList></Reference><Reference><Citation>Riar A.K., Burstein S.R., Palomo G.M., Arreguin A., Manfredi G., Germain D. Sex specific activation of the ER&#x3b1; axis of the mitochondrial UPR (UPRmt) in the G93A-SOD1 mouse model of familial ALS. Hum. Mol. Genet. 2017;26(7):1318&#x2013;1327. doi: 10.1093/hmg/ddx049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx049</ArticleId><ArticleId IdType="pmc">PMC6075578</ArticleId><ArticleId IdType="pubmed">28186560</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese V., Cornelius C., Cuzzocrea S., Iavicoli I., Rizzarelli E., Calabrese E.J. Hormesis, cellular stress response and vitagenes as critical determinants in aging and longevity. Mol. Aspects Med. 2011;32(4-6):279&#x2013;304. doi: 10.1016/j.mam.2011.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mam.2011.10.007</ArticleId><ArticleId IdType="pubmed">22020114</ArticleId></ArticleIdList></Reference><Reference><Citation>Trovato S.A., Pennisi M., Di Paola R., Scuto M., Crupi R., Cambria M.T., Ontario M.L., Tomasello M., Uva M., Maiolino L., Calabrese E.J., Cuzzocrea S., Calabrese V. Neuroinflammation and neurohormesis in the pathogenesis of Alzheimer&#x2019;s disease and Alzheimer-linked pathologies: modulation by nutritional mushrooms. Immun. Ageing. 2018;15(1):8. doi: 10.1186/s12979-017-0108-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-017-0108-1</ArticleId><ArticleId IdType="pmc">PMC5813410</ArticleId><ArticleId IdType="pubmed">29456585</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel S., Champ C., Day J., Aarts E., Bahr B.A., Bakker M., B&#xe1;n&#xe1;ti D., Calabrese V., Cederholm T., Cryan J., Dye L., Farrimond J.A., Korosi A., Lay&#xe9; S., Maudsley S., Milenkovic D., Mohajeri M.H., Sijben J., Solomon A., Spencer J.P.E., Thuret S., Vanden Berghe W., Vauzour D., Vellas B., Wesnes K., Willatts P., Wittenberg R., Geurts L. Poor cognitive ageing: Vulnerabilities, mechanisms and the impact of nutritional interventions. Ageing Res. Rev. 2018;42:40&#x2013;55. doi: 10.1016/j.arr.2017.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2017.12.004</ArticleId><ArticleId IdType="pubmed">29248758</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese V., Giordano J., Ruggieri M., Berritta D., Trovato A., Ontario M.L., Bianchini R., Calabrese E.J. Hormesis, cellular stress response, and redox homeostasis in autism spectrum disorders. J. Neurosci. Res. 2016;94(12):1488&#x2013;1498. doi: 10.1002/jnr.23893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23893</ArticleId><ArticleId IdType="pubmed">27642708</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese E.J., Mattson M.P. How does hormesis impact biology, toxicology, and medicine? NPJ Aging Mech. Dis. 2017;3(1):13. doi: 10.1038/s41514-017-0013-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41514-017-0013-z</ArticleId><ArticleId IdType="pmc">PMC5601424</ArticleId><ArticleId IdType="pubmed">28944077</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese V., Giordano J., Signorile A., Laura O.M., Castorina S., De Pasquale C., Eckert G., Calabrese E.J. Major pathogenic mechanisms in vascular dementia: Roles of cellular stress response and hormesis in neuroprotection. J. Neurosci. Res. 2016;94(12):1588&#x2013;1603. doi: 10.1002/jnr.23925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23925</ArticleId><ArticleId IdType="pubmed">27662637</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese V., Mancuso C., Calvani M., Rizzarelli E., Butterfield D.A., Giuffrida Stella A.M. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. 2007;8(10):766&#x2013;775. doi: 10.1038/nrn2214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2214</ArticleId><ArticleId IdType="pubmed">17882254</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso C., Pani G., Calabrese V. Bilirubin: an endogenous scavenger of nitric oxide and reactive nitrogen species. Redox Rep. 2006;11(5):207&#x2013;213. doi: 10.1179/135100006X154978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/135100006X154978</ArticleId><ArticleId IdType="pubmed">17132269</ArticleId></ArticleIdList></Reference><Reference><Citation>Milane A., Vautier S., Chacun H., Meininger V., Bensimon G., Farinotti R., Fernandez C. Interactions between riluzole and ABCG2/BCRP transporter. Neurosci. Lett. 2009;452(1):12&#x2013;16. doi: 10.1016/j.neulet.2008.12.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2008.12.061</ArticleId><ArticleId IdType="pubmed">19146924</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Xu Z.F., Liu W., Xu B., Yang H.B., Wei Y.G. Riluzole-triggered GSH synthesis via activation of glutamate transporters to antagonize methylmercury-induced oxidative stress in rat cerebral cortex. Oxid. Med. Cell. Longev. 2012;2012:1&#x2013;12. doi: 10.1155/2012/534705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/534705</ArticleId><ArticleId IdType="pmc">PMC3432391</ArticleId><ArticleId IdType="pubmed">22966415</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow R.H., Parks J.K., Pattee G., Parker W.D., Jr Role of mitochondria in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis and other motor neuron disorders: official publication of the World Federation of Neurology. Research Group on Motor Neuron Diseases. 2000;1(3):185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464951</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz M.P. Edaravone (Radicava): A novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis. P&amp;T. 2018;43(1):25&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5737249</ArticleId><ArticleId IdType="pubmed">29290672</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K., Iwasaki Y. Edaravone, a free radical scavenger, delayed symptomatic and pathological progression of motor neuron disease in the wobbler mouse. PLoS One. 2015;10(10):e0140316. doi: 10.1371/journal.pone.0140316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0140316</ArticleId><ArticleId IdType="pmc">PMC4607459</ArticleId><ArticleId IdType="pubmed">26469273</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Hendrix S., Dickson S.P., Knowlton N., Berry J.D., Elliott M.A., Maiser S., Karam C., Caress J.B., Owegi M.A., Quick A., Wymer J., Goutman S.A., Heitzman D., Heiman-Patterson T.D., Jackson C., Quinn C., Rothstein J.D., Kasarskis E.J., Katz J., Jenkins L., Ladha S.S., Miller T.M., Scelsa S.N., Vu T.H., Fournier C., Johnson K.M., Swenson A., Goyal N., Pattee G.L., Babu S., Chase M., Dagostino D., Hall M., Kittle G., Eydinov M., Ostrow J., Pothier L., Randall R., Shefner J.M., Sherman A.V., Tustison E., Vigneswaran P., Yu H., Cohen J., Klee J., Tanzi R., Gilbert W., Yeramian P., Cudkowicz M. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. J. Neurol. Neurosurg. Psychiatry. 2022;93(8):871&#x2013;875. doi: 10.1136/jnnp-2022-329024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2022-329024</ArticleId><ArticleId IdType="pmc">PMC9304116</ArticleId><ArticleId IdType="pubmed">35577511</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Hendrix S., Dickson S.P., Knowlton N., Macklin E.A., Berry J.D., Elliott M.A., Maiser S., Karam C., Caress J.B., Owegi M.A., Quick A., Wymer J., Goutman S.A., Heitzman D., Heiman-Patterson T.D., Jackson C.E., Quinn C., Rothstein J.D., Kasarskis E.J., Katz J., Jenkins L., Ladha S., Miller T.M., Scelsa S.N., Vu T.H., Fournier C.N., Glass J.D., Johnson K.M., Swenson A., Goyal N.A., Pattee G.L., Andres P.L., Babu S., Chase M., Dagostino D., Hall M., Kittle G., Eydinov M., McGovern M., Ostrow J., Pothier L., Randall R., Shefner J.M., Sherman A.V., St Pierre M.E., Tustison E., Vigneswaran P., Walker J., Yu H., Chan J., Wittes J., Yu Z.F., Cohen J., Klee J., Leslie K., Tanzi R.E., Gilbert W., Yeramian P.D., Schoenfeld D., Cudkowicz M.E. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31&#x2013;39. doi: 10.1002/mus.27091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27091</ArticleId><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Macklin E.A., Hendrix S., Berry J.D., Elliott M.A., Maiser S., Karam C., Caress J.B., Owegi M.A., Quick A., Wymer J., Goutman S.A., Heitzman D., Heiman-Patterson T., Jackson C.E., Quinn C., Rothstein J.D., Kasarskis E.J., Katz J., Jenkins L., Ladha S., Miller T.M., Scelsa S.N., Vu T.H., Fournier C.N., Glass J.D., Johnson K.M., Swenson A., Goyal N.A., Pattee G.L., Andres P.L., Babu S., Chase M., Dagostino D., Dickson S.P., Ellison N., Hall M., Hendrix K., Kittle G., McGovern M., Ostrow J., Pothier L., Randall R., Shefner J.M., Sherman A.V., Tustison E., Vigneswaran P., Walker J., Yu H., Chan J., Wittes J., Cohen J., Klee J., Leslie K., Tanzi R.E., Gilbert W., Yeramian P.D., Schoenfeld D., Cudkowicz M.E. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N. Engl. J. Med. 2020;383(10):919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano M., Emmanuele V., Quinzii C.M. Emerging therapies for mitochondrial diseases. Essays Biochem. 2018;62(3):467&#x2013;481. doi: 10.1042/EBC20170114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/EBC20170114</ArticleId><ArticleId IdType="pmc">PMC6104515</ArticleId><ArticleId IdType="pubmed">29980632</ArticleId></ArticleIdList></Reference><Reference><Citation>Taivassalo T., Shoubridge E.A., Chen J., Kennaway N.G., DiMauro S., Arnold D.L., Haller R.G. Aerobic conditioning in patients with mitochondrial myopathies: Physiological, biochemical, and genetic effects. Ann. Neurol. 2001;50(2):133&#x2013;141. doi: 10.1002/ana.1050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.1050</ArticleId><ArticleId IdType="pubmed">11506394</ArticleId></ArticleIdList></Reference><Reference><Citation>Siciliano G, Simoncini C, Lo Gerfo A, Orsucci D, Ricci G, Mancuso M. Effects of aerobic training on exercise-related oxidative stress in mitochondrial myopathies. Neuromuscular Disorders: NMD. 2012;3(3-3):S172-7. doi: 10.1016/j.nmd.2012.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2012.10.005</ArticleId><ArticleId IdType="pmc">PMC3526792</ArticleId><ArticleId IdType="pubmed">23182634</ArticleId></ArticleIdList></Reference><Reference><Citation>Taivassalo T., Gardner J.L., Taylor R.W., Schaefer A.M., Newman J., Barron M.J., Haller R.G., Turnbull D.M. Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain. 2006;129(12):3391&#x2013;3401. doi: 10.1093/brain/awl282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl282</ArticleId><ArticleId IdType="pubmed">17085458</ArticleId></ArticleIdList></Reference><Reference><Citation>Merico A., Cavinato M., Gregorio C., Lacatena A., Gioia E., Piccione F., Angelini C. Effects of combined endurance and resistance training in Amyotrophic Lateral Sclerosis: A pilot, randomized, controlled study. Eur. J. Transl. Myol. 2018;28(1):7278. doi: 10.4081/ejtm.2018.7278.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/ejtm.2018.7278</ArticleId><ArticleId IdType="pmc">PMC5895987</ArticleId><ArticleId IdType="pubmed">29686818</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeili M.A., Yadav S., Gupta R.K., Waggoner G.R., Deloach A., Calingasan N.Y., Beal M.F., Kiaei M. Preferential PPAR-&#x3b1; activation reduces neuroinflammation, and blocks neurodegeneration in vivo. Hum. Mol. Genet. 2016;25(2):317&#x2013;327. doi: 10.1093/hmg/ddv477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv477</ArticleId><ArticleId IdType="pmc">PMC4706116</ArticleId><ArticleId IdType="pubmed">26604138</ArticleId></ArticleIdList></Reference><Reference><Citation>Paraskevas G.P., Kapaki E., Libitaki G., Zournas C., Segditsa I., Papageorgiou C. Ascorbate in healthy subjects, amyotrophic lateral sclerosis and Alzheimer&#x2019;s disease. Acta Neurol. Scand. 1997;96(2):88&#x2013;90. doi: 10.1111/j.1600-0404.1997.tb00245.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1997.tb00245.x</ArticleId><ArticleId IdType="pubmed">9272183</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Cutting F.B., Zhai P., Doble A., Taylor C.P., Andrus P.K., Hall E.D. Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 1996;39(2):147&#x2013;157. doi: 10.1002/ana.410390203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410390203</ArticleId><ArticleId IdType="pubmed">8967745</ArticleId></ArticleIdList></Reference><Reference><Citation>Desnuelle C., Dib M., Garrel C., Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2001;2(1):9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">11465936</ArticleId></ArticleIdList></Reference><Reference><Citation>Stacpoole P.W., deGrauw T.J., Feigenbaum A.S., Hoppel C., Kerr D.S., McCandless S.E., Miles M.V., Robinson B.H., Tang P.H. Design and implementation of the first randomized controlled trial of coenzyme Q10 in children with primary mitochondrial diseases. Mitochondrion. 2012;12(6):623&#x2013;629. doi: 10.1016/j.mito.2012.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2012.09.005</ArticleId><ArticleId IdType="pmc">PMC3975832</ArticleId><ArticleId IdType="pubmed">23022402</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T., Inagaki M., Hidaka H. Calcium-dependent interactions with calmodulin of a fluorescent calmodulin antagonist: N2-dansyl-l-arginine-4-t-butylpiperidine amide. Arch. Biochem. Biophys. 1983;220(1):188&#x2013;192. doi: 10.1016/0003-9861(83)90399-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-9861(83)90399-5</ArticleId><ArticleId IdType="pubmed">6830230</ArticleId></ArticleIdList></Reference><Reference><Citation>Littarru G.P., Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol. Biotechnol. 2007;37(1):31&#x2013;37. doi: 10.1007/s12033-007-0052-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12033-007-0052-y</ArticleId><ArticleId IdType="pubmed">17914161</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Antona S., Caramenti M., Porro D., Castiglioni I., Cava C. Amyotrophic lateral sclerosis: A diet review. Foods. 2021;10(12):3128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8702143</ArticleId><ArticleId IdType="pubmed">34945679</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K. Glutathione in the nervous system as a potential therapeutic target to control the development and progression of amyotrophic lateral sclerosis. Antioxidants. 2021;10(7):1011. doi: 10.3390/antiox10071011.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10071011</ArticleId><ArticleId IdType="pmc">PMC8300718</ArticleId><ArticleId IdType="pubmed">34201812</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., del Valle J., Modol L., Martinez A., Granado-Serrano A.B., Ramirez-N&#xfa;&#xf1;ez O., Pall&#xe1;s M., Portero-Otin M., Osta R., Navarro X. Resveratrol improves motoneuron function and extends survival in SOD1G93A ALS mice. Neurotherapeutics. 2014;11(2):419&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3996124</ArticleId><ArticleId IdType="pubmed">24414863</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuguchi Y., Hatakeyama H., Sueoka K., Tanaka M., Goto Y. Low dose resveratrol ameliorates mitochondrial respiratory dysfunction and enhances cellular reprogramming. Mitochondrion. 2017;34:43&#x2013;48. doi: 10.1016/j.mito.2016.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2016.12.006</ArticleId><ArticleId IdType="pubmed">28093354</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., del Valle J., Morell M., Pall&#xe1;s M., Osta R., Navarro X. Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G93A ALS mice: overlapping effects or limited therapeutic opportunity? Orphanet J. Rare Dis. 2014;9(1):78. doi: 10.1186/1750-1172-9-78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-9-78</ArticleId><ArticleId IdType="pmc">PMC4035830</ArticleId><ArticleId IdType="pubmed">24885036</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnaraj R.N., Kumari S.S.S., Mukhopadhyay S.S. Antagonistic molecular interactions of photosynthetic pigments with molecular disease targets: a new approach to treat AD and ALS. J. Recept. Signal Transduct. Res. 2016;36(1):67&#x2013;71. doi: 10.3109/10799893.2015.1024851.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10799893.2015.1024851</ArticleId><ArticleId IdType="pubmed">26053508</ArticleId></ArticleIdList></Reference><Reference><Citation>Korkmaz O.T., Aytan N., Carreras I., Choi J.K., Kowall N.W., Jenkins B.G., Dedeoglu A. 7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis. Neurosci. Lett. 2014;566:286&#x2013;291. doi: 10.1016/j.neulet.2014.02.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2014.02.058</ArticleId><ArticleId IdType="pmc">PMC5906793</ArticleId><ArticleId IdType="pubmed">24637017</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh S.H., Lee S.M., Kim H.Y., Lee K.Y., Lee Y.J., Kim H.T., Kim J., Kim M.H., Hwang M.S., Song C., Yang K.W., Lee K.W., Kim S.H., Kim O.H. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci. Lett. 2006;395(2):103&#x2013;107. doi: 10.1016/j.neulet.2005.10.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2005.10.056</ArticleId><ArticleId IdType="pubmed">16356650</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Chen S., Li X., Luo G., Li L., Le W. Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis. Neurochem. Res. 2006;31(10):1263&#x2013;1269. doi: 10.1007/s11064-006-9166-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-006-9166-z</ArticleId><ArticleId IdType="pubmed">17021948</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrera-Juli&#xe1; S., Moreno M.L., Barrios C., de la Rubia Ort&#xed; J.E., Drehmer E. Antioxidant alternatives in the treatment of amyotrophic lateral sclerosis: A comprehensive review. Front. Physiol. 2020:11. doi: 10.3389/fphys.2020.00063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2020.00063</ArticleId><ArticleId IdType="pmc">PMC7016185</ArticleId><ArticleId IdType="pubmed">32116773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi M., Agah E., Nafissi S., Jaafari M.R., Harirchian M.H., Sarraf P., Faghihi-Kashani S., Hosseini S.J., Ghoreishi A., Aghamollaii V., Hosseini M., Tafakhori A. Safety and efficacy of nanocurcumin as add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A pilot randomized clinical trial. Neurotherapeutics. 2018;15(2):430&#x2013;438. doi: 10.1007/s13311-018-0606-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-018-0606-7</ArticleId><ArticleId IdType="pmc">PMC5935637</ArticleId><ArticleId IdType="pubmed">29352425</ArticleId></ArticleIdList></Reference><Reference><Citation>Weishaupt J.H., Bartels C., P&#xf6;lking E., Dietrich J., Rohde G., Poeggeler B., Mertens N., Sperling S., Bohn M., H&#xfc;ther G., Schneider A., Bach A., Sir&#xe9;n A.L., Hardeland R., B&#xe4;hr M., Nave K.A., Ehrenreich H. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal Res. 2006;41(4):313&#x2013;323. doi: 10.1111/j.1600-079X.2006.00377.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2006.00377.x</ArticleId><ArticleId IdType="pubmed">17014688</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Cook A., Kim J., Baranov S.V., Jiang J., Smith K., Cormier K., Bennett E., Browser R.P., Day A.L., Carlisle D.L., Ferrante R.J., Wang X., Friedlander R.M. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2013;55:26&#x2013;35. doi: 10.1016/j.nbd.2013.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.03.008</ArticleId><ArticleId IdType="pmc">PMC3652329</ArticleId><ArticleId IdType="pubmed">23537713</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel E., Cassina A., Mart&#xed;nez-Palma L., Souza J.M., Bolatto C., Rodr&#xed;guez-Bottero S., Logan A., Smith R.A.J., Murphy M.P., Barbeito L., Radi R., Cassina P. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2014;70:204&#x2013;213. doi: 10.1016/j.freeradbiomed.2014.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.02.019</ArticleId><ArticleId IdType="pubmed">24582549</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M.E., van den Berg L.H., Shefner J.M., Mitsumoto H., Mora J.S., Ludolph A., Hardiman O., Bozik M.E., Ingersoll E.W., Archibald D., Meyers A.L., Dong Y., Farwell W.R., Kerr D.A. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12(11):1059&#x2013;1067. doi: 10.1016/S1474-4422(13)70221-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70221-7</ArticleId><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., Zha J., Liu J., Di J. Minocycline impedes mitochondrial-dependent cell death and stabilizes expression of hypoxia inducible factor-1&#x3b1; in spinal cord injury. Arch. Med. Sci. 2019;15(2):475&#x2013;483. doi: 10.5114/aoms.2018.73520.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms.2018.73520</ArticleId><ArticleId IdType="pmc">PMC6425201</ArticleId><ArticleId IdType="pubmed">30899301</ArticleId></ArticleIdList></Reference><Reference><Citation>Orsucci D., Ienco E.C., Siciliano G., Mancuso M. Mitochondrial disorders and drugs: what every physician should know. Drugs Context. 2019;8:1&#x2013;16. doi: 10.7573/dic.212588.</Citation><ArticleIdList><ArticleId IdType="doi">10.7573/dic.212588</ArticleId><ArticleId IdType="pmc">PMC6668504</ArticleId><ArticleId IdType="pubmed">31391854</ArticleId></ArticleIdList></Reference><Reference><Citation>Tourniaire F., Musinovic H., Gouranton E., Astier J., Marcotorchino J., Arreguin A., Bernot D., Palou A., Bonet M.L., Ribot J., Landrier J.F. All-trans retinoic acid induces oxidative phosphorylation and mitochondria biogenesis in adipocytes. J. Lipid Res. 2015;56(6):1100&#x2013;1109. doi: 10.1194/jlr.M053652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M053652</ArticleId><ArticleId IdType="pmc">PMC4442868</ArticleId><ArticleId IdType="pubmed">25914170</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen M.C.H., Koene S., Laat P., Hemelaar P., Pickkers P., Spaans E., Beukema R., Beyrath J., Groothuis J., Verhaak C., Smeitink J. The KHENERGY study: Safety and efficacy of KH 176 in mitochondrial m.3243A&gt;G spectrum disorders. Clin. Pharmacol. Ther. 2019;105(1):101&#x2013;111. doi: 10.1002/cpt.1197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1197</ArticleId><ArticleId IdType="pmc">PMC6704357</ArticleId><ArticleId IdType="pubmed">30058726</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele H., Gomez-Duran A., Pyle A., Hopton S., Newman J., Stefanetti R.J., Charman S.J., Parikh J.D., He L., Viscomi C., Jakovljevic D.G., Hollingsworth K.G., Robinson A.J., Taylor R.W., Bottolo L., Horvath R., Chinnery P.F. Metabolic effects of bezafibrate in mitochondrial disease. EMBO Mol. Med. 2020;12(3):e11589. doi: 10.15252/emmm.201911589.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201911589</ArticleId><ArticleId IdType="pmc">PMC7059007</ArticleId><ArticleId IdType="pubmed">32107855</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros C.D.S., Livramento J.B., Mouro M.G., Higa E.M.S., Moraes C.T., Tengan C.H. L-Arginine reduces nitro-oxidative stress in cultured cells with mitochondrial deficiency. Nutrients. 2021;13(2):534. doi: 10.3390/nu13020534.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13020534</ArticleId><ArticleId IdType="pmc">PMC7914615</ArticleId><ArticleId IdType="pubmed">33562042</ArticleId></ArticleIdList></Reference><Reference><Citation>Civiletto G., Dogan S.A., Cerutti R., Fagiolari G., Moggio M., Lamperti C., Beninc&#xe1; C., Viscomi C., Zeviani M. Rapamycin rescues mitochondrial myopathy via coordinated activation of autophagy and lysosomal biogenesis. EMBO Mol. Med. 2018;10(11):e8799. doi: 10.15252/emmm.201708799.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201708799</ArticleId><ArticleId IdType="pmc">PMC6220341</ArticleId><ArticleId IdType="pubmed">30309855</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinelli D., Catteruccia M., Piemonte F., Pastore A., Tozzi G., Dionisi-Vici C., Pontrelli G., Corsetti T., Livadiotti S., Kheifets V., Hinman A., Shrader W.D., Thoolen M., Klein M.B., Bertini E., Miller G. EPI-743 reverses the progression of the pediatric mitochondrial disease&#x2014;Genetically defined Leigh Syndrome. Mol. Genet. Metab. 2012;107(3):383&#x2013;388. doi: 10.1016/j.ymgme.2012.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgme.2012.09.007</ArticleId><ArticleId IdType="pubmed">23010433</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgio V., Petronilli V., Ghelli A., Carelli V., Rugolo M., Lenaz G., Bernardi P. The effects of idebenone on mitochondrial bioenergetics. Biochim. Biophys. Acta Bioenerg. 2012;1817(2):363&#x2013;369. doi: 10.1016/j.bbabio.2011.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbabio.2011.10.012</ArticleId><ArticleId IdType="pmc">PMC3265671</ArticleId><ArticleId IdType="pubmed">22086148</ArticleId></ArticleIdList></Reference><Reference><Citation>Guha S., Konkwo C., Lavorato M., Mathew N.D., Peng M., Ostrovsky J., Kwon Y.J., Polyak E., Lightfoot R., Seiler C., Xiao R., Bennett M., Zhang Z., Nakamaru-Ogiso E., Falk M.J. Pre-clinical evaluation of cysteamine bitartrate as a therapeutic agent for mitochondrial respiratory chain disease. Hum. Mol. Genet. 2019;28(11):1837&#x2013;1852. doi: 10.1093/hmg/ddz023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddz023</ArticleId><ArticleId IdType="pmc">PMC6522065</ArticleId><ArticleId IdType="pubmed">30668749</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeti R., Baccaro A., Esteras N., Giunti P. Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich&#x2019;s ataxia models. Front. Cell. Neurosci. 2018;12:188. doi: 10.3389/fncel.2018.00188.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00188</ArticleId><ArticleId IdType="pmc">PMC6056642</ArticleId><ArticleId IdType="pubmed">30065630</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H., Jin Y., Wei J., Jin H., Sha D., Wu J.Y. Mode of action of taurine as a neuroprotector. Brain Res. 2005;1038(2):123&#x2013;131. doi: 10.1016/j.brainres.2005.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2005.01.058</ArticleId><ArticleId IdType="pubmed">15757628</ArticleId></ArticleIdList></Reference><Reference><Citation>Rikimaru M., Ohsawa Y., Wolf A.M., Nishimaki K., Ichimiya H., Kamimura N., Nishimatsu S., Ohta S., Sunada Y. Taurine ameliorates impaired the mitochondrial function and prevents stroke-like episodes in patients with MELAS. Intern. Med. 2012;51(24):3351&#x2013;3357. doi: 10.2169/internalmedicine.51.7529.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.51.7529</ArticleId><ArticleId IdType="pubmed">23257519</ArticleId></ArticleIdList></Reference><Reference><Citation>Virmani M.A., Cirulli M. The role of l-carnitine in mitochondria, prevention of metabolic inflexibility and disease initiation. Int. J. Mol. Sci. 2022;23(5):2717. doi: 10.3390/ijms23052717.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23052717</ArticleId><ArticleId IdType="pmc">PMC8910660</ArticleId><ArticleId IdType="pubmed">35269860</ArticleId></ArticleIdList></Reference><Reference><Citation>Liufu T., Wang Z. Treatment for mitochondrial diseases. Rev. Neurosci. 2021;32(10):35&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">32903211</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry E.A., Bennett C.F., Luo C., Balsa E., Jedrychowski M., O&#x2019;Malley K.E., Latorre-Muro P., Ladley R.P., Reda K., Wright P.M., Gygi S.P., Myers A.G., Puigserver P. Tetracyclines promote survival and fitness in mitochondrial disease models. Nat. Metab. 2021;3(1):33&#x2013;42. doi: 10.1038/s42255-020-00334-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-020-00334-y</ArticleId><ArticleId IdType="pmc">PMC7856165</ArticleId><ArticleId IdType="pubmed">33462515</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh J.H., Wang K.C., Kaizaki A., Lee J.W., Wei H.C., Tucci M.A., Ojeda N.B., Fan L.W., Tien L.T. Pioglitazone ameliorates lipopolysaccharide-induced behavioral impairment, brain inflammation, white matter injury and mitochondrial dysfunction in neonatal rats. Int. J. Mol. Sci. 2021;22(12):6306. doi: 10.3390/ijms22126306.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22126306</ArticleId><ArticleId IdType="pmc">PMC8231261</ArticleId><ArticleId IdType="pubmed">34208374</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Zhang X., Meng L., Gong M., Li J., Shi W., Qiu J., Yang Y., Zhao J., Suo Y., Liang X., Wang X., Tse G., Jiang N., Li G., Zhao Y., Liu T. Pioglitazone inhibits diabetes-induced atrial mitochondrial oxidative stress and improves mitochondrial biogenesis, dynamics, and function through the PPAR-&#x3b3;/PGC-1&#x3b1; signaling pathway. Front. Pharmacol. 2021;12:658362. doi: 10.3389/fphar.2021.658362.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.658362</ArticleId><ArticleId IdType="pmc">PMC8237088</ArticleId><ArticleId IdType="pubmed">34194324</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein Gunnewiek T.M., Verboven A.H.A., Pelgrim I., Hogeweg M., Schoenmaker C., Renkema H., Beyrath J., Smeitink J., de Vries B.B.A., Hoen P.B.A.C., Kozicz T., Nadif Kasri N. Sonlicromanol improves neuronal network dysfunction and transcriptome changes linked to m.3243A&gt;G heteroplasmy in iPSC-derived neurons. Stem Cell Reports. 2021;16(9):2197&#x2013;2212. doi: 10.1016/j.stemcr.2021.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2021.07.002</ArticleId><ArticleId IdType="pmc">PMC8452519</ArticleId><ArticleId IdType="pubmed">34329596</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y., Luo Y.F., Liu S.Q., Ma J.P., Liu F.P., Fang Y. Pentacyclic triterpene oleanolic acid protects against cardiac aging through regulation of mitophagy and mitochondrial integrity. Bba-Mol. Basis Dis. 2022;1868(7)</Citation><ArticleIdList><ArticleId IdType="pubmed">35346820</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogleman S., Santana C., Bishop C., Miller A., Capco D.G. CRISPR/Cas9 and mitochondrial gene replacement therapy: promising techniques and ethical considerations. Am. J. Stem Cells. 2016;5(2):39&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5043096</ArticleId><ArticleId IdType="pubmed">27725916</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai P.K., Craven L., Hoogewijs K., Russell O.M., Lightowlers R.N. Advances in methods for reducing mitochondrial DNA disease by replacing or manipulating the mitochondrial genome. Essays Biochem. 2018;62(3):455&#x2013;465. doi: 10.1042/EBC20170113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/EBC20170113</ArticleId><ArticleId IdType="pmc">PMC6056713</ArticleId><ArticleId IdType="pubmed">29950320</ArticleId></ArticleIdList></Reference><Reference><Citation>C&#xe1;mara Y., Gonz&#xe1;lez-Vioque E., Scarpelli M., Torres-Torronteras J., Caballero A., Hirano M., Mart&#xed; R. Administration of deoxyribonucleosides or inhibition of their catabolism as a pharmacological approach for mitochondrial DNA depletion syndrome. Hum. Mol. Genet. 2014;23(9):2459&#x2013;2467. doi: 10.1093/hmg/ddt641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt641</ArticleId><ArticleId IdType="pmc">PMC6281351</ArticleId><ArticleId IdType="pubmed">24362886</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Vioque E., Torres-Torronteras J., Andreu A.L., Mart&#xed; R. Limited dCTP availability accounts for mitochondrial DNA depletion in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). PLoS Genet. 2011;7(3):e1002035. doi: 10.1371/journal.pgen.1002035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002035</ArticleId><ArticleId IdType="pmc">PMC3069123</ArticleId><ArticleId IdType="pubmed">21483760</ArticleId></ArticleIdList></Reference><Reference><Citation>Bax B.E., Bain M.D., Scarpelli M., Filosto M., Tonin P., Moran N. Clinical and biochemical improvements in a patient with MNGIE following enzyme replacement. Neurology. 2013;81(14):1269&#x2013;1271. doi: 10.1212/WNL.0b013e3182a6cb4b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a6cb4b</ArticleId><ArticleId IdType="pmc">PMC3795612</ArticleId><ArticleId IdType="pubmed">23966250</ArticleId></ArticleIdList></Reference><Reference><Citation>Halter J.P., Michael W., Sch&#xfc;pbach M., Mandel H., Casali C., Orchard K., Collin M., Valcarcel D., Rovelli A., Filosto M., Dotti M.T., Marotta G., Pintos G., Barba P., Accarino A., Ferra C., Illa I., Beguin Y., Bakker J.A., Boelens J.J., de Coo I.F.M., Fay K., Sue C.M., Nachbaur D., Zoller H., Sobreira C., Pinto Simoes B., Hammans S.R., Savage D., Mart&#xed; R., Chinnery P.F., Elhasid R., Gratwohl A., Hirano M. Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain. 2015;138(10):2847&#x2013;2858. doi: 10.1093/brain/awv226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv226</ArticleId><ArticleId IdType="pmc">PMC4836400</ArticleId><ArticleId IdType="pubmed">26264513</ArticleId></ArticleIdList></Reference><Reference><Citation>Peverelli L., Catania A., Marchet S., Ciasca P., Cammarata G., Melzi L. Leber&#x2019;s hereditary optic neuropathy: A report on novel mtDNA pathogenic variants. Front. Neurol. 2021;12:657317. doi: 10.3389/fneur.2021.657317.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.657317</ArticleId><ArticleId IdType="pmc">PMC8220086</ArticleId><ArticleId IdType="pubmed">34177762</ArticleId></ArticleIdList></Reference><Reference><Citation>Slone J., Huang T. The special considerations of gene therapy for mitochondrial diseases. NPJ Genom. Med. 2020;5(1):7. doi: 10.1038/s41525-020-0116-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41525-020-0116-5</ArticleId><ArticleId IdType="pmc">PMC7051955</ArticleId><ArticleId IdType="pubmed">32140258</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava S., Moraes C.T. Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease. Hum. Mol. Genet. 2001;10(26):3093&#x2013;3099. doi: 10.1093/hmg/10.26.3093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/10.26.3093</ArticleId><ArticleId IdType="pubmed">11751691</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexeyev M.F., Venediktova N., Pastukh V., Shokolenko I., Bonilla G., Wilson G.L. Selective elimination of mutant mitochondrial genomes as therapeutic strategy for the treatment of NARP and MILS syndromes. Gene Ther. 2008;15(7):516&#x2013;523. doi: 10.1038/gt.2008.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2008.11</ArticleId><ArticleId IdType="pmc">PMC10416612</ArticleId><ArticleId IdType="pubmed">18256697</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M., Borgeld H-J., Zhang J., Shin-ichi M., Gong J-S., Yoneda M., Maruyama W., Naoi M., Ibi T., Sahashi K., Shamoto M., Fuku N., Kurata M., Yamada Y., Nishizawa K., Akao Y., Ohishi N., Miyabayashi S., Umemoto H., Muramatsu T., Furukawa K., Kikuchi A., Nakano I., Ozawa K., Yagi K. Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J. Biomed. Sci. 2002;9(6 Pt 1):534&#x2013;541. doi: 10.1159/000064726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000064726</ArticleId><ArticleId IdType="pubmed">12372991</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Guan M.X. Human mitochondrial leucyl-tRNA synthetase corrects mitochondrial dysfunctions due to the tRNA Leu(UUR) A3243G mutation, associated with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms and diabetes. Mol. Cell. Biol. 2010;30(9):2147&#x2013;2154. doi: 10.1128/MCB.01614-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01614-09</ArticleId><ArticleId IdType="pmc">PMC2863588</ArticleId><ArticleId IdType="pubmed">20194621</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbah H.N., Gupta R.C., Kohli S., Wang M., Hachem S., Zhang K. Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circ. Heart Fail. 2016;9(2):e002206. doi: 10.1161/CIRCHEARTFAILURE.115.002206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.115.002206</ArticleId><ArticleId IdType="pmc">PMC4743543</ArticleId><ArticleId IdType="pubmed">26839394</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>